



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003827 M 07/08/1978 45 Y

Molecular

Collected: 08/31/2023 10:33 Received: 08/31/2023 10:33

Table with 6 columns: Test Name, Result, Flag, Ref-Ranges, Units, Site. Row 1: BCR-ABL1 Major (p210) Rearrangement, Quantitative PCR. Row 2: p210 Result, DETECTED, AB, see below, WMRL. Row 3: p210 %IS, >50.000, H, see below, %, WMRL. Row 4: p210 MR, <0.3, L, see below, WMRL. Row 5: BCR-ABL1 Major (p210) Comment, see below, see below, WMRL.

The transcript for the p210 product was detected at the stated MR/%IS. This test does not differentiate between e13a2 or e14a2 fusion transcripts and does not monitor other rare fusion transcripts resulting from t(9;22). This test is not intended for the diagnosis of CML.

This test was performed using the QuantideX® qPCR BCR-ABL IS Kit (Assuragen). The QuantideX® qPCR BCR-ABL IS kit is an in vitro nucleic acid amplification test for the quantitation of BCR-ABL1 and ABL1 transcripts in total RNA from whole blood of diagnosed t(9;22) positive Chronic Myeloid Leukemia (CML) patients expressing BCR-ABL1 fusion transcripts type e13a2 and/or e14a2. The QuantideX® qPCR BCR-ABL IS Kit is a reverse transcription-quantitative PCR performed on the Applied Biosystems 7500 Fast Dx Real-Time OCR Instrument and is intended to measure BCR-ABL1 to ABL1, expressed as a log molecular reduction (MR value) from a baseline of 100% on the International Scale, in t(9;22) positive CML patients during monitoring of treatment with Tyrosine Kinase Inhibitors (TKIs).

Performing Site:

WMRL: WARDE MEDICAL LABORATORY 300 West Textile Road Ann Arbor MI 48108

Reported Date: 2023.09.05 8:42 BCRMJ

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

F231000017
WX0000003827
Printed D&T: 09/05/23 08:42

Ordered By: KAJAL SITWALA, MD, PhD
WX000000000002365

Kajal V. Sitwala, MD, PhD - Medical Director
Form: MM RL1
PAGE 1 OF 1